May 9th 2024
In an interview with Targeted Oncology, Shilpa Gupta, MD, discussed the rationale and potential significance of the MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Expert Discusses Sequential Therapy Benefits for Patients With Muscle-Invasive Bladder Cancer
September 8th 2016Though the current standard of care when treating muscle-invasive bladder cancer calls for neoadjuvant chemotherapy followed by radical cystectomy, the procedure is associated with a fair amount of morbidity and is not suggested lightly, according to Stanley Yap, MD.
Read More
HHLA2 Vs PD-L1 Expression in Urothelial Tumors
September 1st 2016Alexander I. Sankin, MD, assistant professor of Urology at Montefiore Medical Center at the Albert Einstein College of Medicine, discusses the differences between the recently defined checkpoint HHLA2 and PD-L1 expression in urothelial tumors, as well as next steps in this space.
Watch
Poch Discusses Key Immunotherapy Advancements in Treatment of Bladder Cancer
August 30th 2016The field of metastatic bladder cancer—an area that had long been stagnant—has quickly evolved with the recent FDA approval of atezolizumab (Tecentriq) coupled with the breakthrough therapy designation of nivolumab (Opdivo).
Read More
FDA Approval of Atezolizumab Poised to Significantly Change Treatment Paradigm in Bladder Cancer
August 17th 2016The treatment paradigm of metastatic urothelial carcinoma was shaken up in May 2016 when the FDA approved the PD-L1 inhibitor atezolizumab for the treatment of patients with locally advanced or metastatic disease.
Read More
Following Favorable Findings, Nivolumab Receives Breakthrough Therapy Designation for mUC
July 15th 2016The FDA has granted nivolumab a breakthrough therapy designation for the treatment of patients with resectable locally advanced or metastatic urothelial carcinoma after the failure of a platinum-containing regimen.
Read More
CAR Therapy Yields High Complete Response Rates in Adults with B-cell ALL in Phase I Trial
June 9th 2016Infusion with 19-28z chimeric antigen receptor (CAR) modified T-cells led to complete response (CR) rates of 77% to 90% and minimal residual disease (MRD)-CR rates of 68% to 70% in adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (B-ALL).
Read More
Novel TKI Examined in Metastatic Breast Cancer Patients with HER2 Mutation
June 8th 2016Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.
Read More
Atezolizumab Could be Future First-Line Therapy for Bladder Cancer
June 7th 2016The immunotherapy agent atezolizumab (Tecentriq) reduced the size of tumors by 24% in patients with metastatic urothelial carcinoma (mUC), according to phase II clinical trial results presented at the 2016 ASCO Annual Meeting.
Read More
Urothelial Carcinoma on Verge of Treatment Revolution
April 7th 2016An upcoming FDA decision for the PD-L1 inhibitor atezolizumab as a treatment for patients with bladder cancer could set the stage for an onslaught of new and highly effective immuno-oncology agents, according to Daniel Petrylak, MD.
Read More
Checkpoint Inhibition Could Shift Standard of Care in Bladder Cancer
March 9th 2016Immune checkpoint inhibitors have shown promising findings for patients with advanced bladder cancer, with data from phase II studies submitted to the FDA for consideration. The next question facing oncologists is how to optimally utilize these agents, according to James L. Gulley, MD, PhD.
Read More
FDA Grants Durvalumab Breakthrough Status for Bladder Cancer
February 18th 2016The FDA has granted a breakthrough therapy designation to durvalumab as a treatment for patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer following progression on prior treatment with a platinum-based regimen.
Read More
Adjuvant Chemotherapy Postcystectomy Elongates Survival in Bladder Cancer
February 6th 2016Adjuvant chemotherapy was associated with improved overall survival (OS) compared with observation postcystectomy in patients with pathologic T3/4 and/or pathologic node-positive bladder cancer, according to a retrospective analysis published in the Journal of Clinical Oncology.
Read More
Complete Response Letter Issued by FDA for Bladder Cancer Immunotherapy MCNA
February 5th 2016The FDA issued a complete response letter to Telesta Therapeutics informing the company that its biologics license application (BLA) for MCNA in bladder cancer would not be approved and that an additional phase III clinical trial was needed to adequately evaluate the immunotherapy.
Read More